InMed Pharmaceuticals (FRA:MWG) Interest Coverage: N/A (As of Mar. 2026)


FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
29 GF Score
Price €1.40
GF Value €0.78
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. InMed Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was €-2.44 Mil. InMed Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for InMed Pharmaceuticals's Interest Coverage or its related term are showing as below:


FRA:MWG's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.75
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


InMed Pharmaceuticals  (FRA:MWG) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


InMed Pharmaceuticals Interest Coverage Related Terms


InMed Pharmaceuticals Interest Coverage Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

InMed Pharmaceuticals Interest Coverage Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 N/A N/A N/A 0.00

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.00 N/A N/A N/A

FRA:MWG vs SNOA, CVSI, PRFX: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Interest Coverage falls into.


FRA:MWG
29GF Score
InMed Pharmaceuticals Inc FRA:MWG
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InMed Pharmaceuticals's Interest Coverage for the fiscal year that ended in Jun. 2025 is calculated as

Here, for the fiscal year that ended in Jun. 2025, InMed Pharmaceuticals's Interest Expense was €-0.32 Mil. Its Operating Income was €-6.87 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.27 Mil.

InMed Pharmaceuticals did not have earnings to cover the interest expense.

InMed Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, InMed Pharmaceuticals's Interest Expense was €0.00 Mil. Its Operating Income was €-2.44 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.03 Mil.

GuruFocus does not calculate InMed Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.40 is trading 79.5% above its estimated GF Value™ of €0.78.

Key valuation signals for FRA:MWG:

  • Interest Coverage: N/A
  • GF Value™: €0.78 vs. price of €1.40 (79.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for FRA:MWG

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price
€0.78
GF Value